A 2023 study further examined GFAP levels in the serum and CSF of patients with AD, dementia with Lewy bodies (DLB), and healthy controls, revealing sex-related differences in CSF GFAP levels exclusively in patients with AD. This evidence concerns the gene GFAP and Lewy body dementia.